Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Rafael Holdings, Inc. (RFL) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/29/2019 GN LipoMedix to Present New Clinical Data on Promitil® at American Association for Cancer Research (AACR) Annual Meeting 2019
03/12/2019 10-Q Quarterly Report for the period ended January 31, 2019
03/12/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Second Quarter Fiscal Year 2019 Results"
03/04/2019 GN Lipomedix Announces Initiation of Phase 1b Trial (LIPORAD-2018) of Promitil® in Combination with Radiotherapy in Patients with Advanced Cancer.
02/08/2019 SC 13G DIMENSIONAL FUND ADVISORS LP reports a 7.1% stake in RAFAEL HOLDINGS INC-CLASS B
01/28/2019 4 ASH MENACHEM (President) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 70,718 shares @ $0
01/23/2019 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Rafael Holdings Acquires Majority Stake in Rafael Pharma"
01/18/2019 4 JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 1,254,200 shares @ $6.89, valued at $8.6M
01/14/2019 8-K Submission of Matters to a Vote of Security Holders
01/10/2019 GN EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals' devimistat (CPI-613??) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
01/10/2019 8-K Other Events
01/10/2019 GN EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals' devimistat (CPI-613®) for Treatment of Metastatic Pancreatic Cancer
01/09/2019 GN UPDATED RELEASE: Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
01/09/2019 GN Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613 in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
01/08/2019 GN Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
01/07/2019 4 GREENBERG STEPHEN M (Director) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 4,203 shares @ $8.47, valued at $35.6k
01/07/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/07/2019 4 WEISS MICHAEL J (Director) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 4,203 shares @ $8.47, valued at $35.6k
12/11/2018 GN Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer
12/10/2018 10-Q Quarterly Report for the period ended October 31, 2018
12/10/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports First Quarter Fiscal Year 2019 Results"
12/06/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentations"
11/29/2018 GN Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
11/27/2018 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/21/2018 8-K Other Events
11/15/2018 PRE 14A Form PRE 14A - Other preliminary proxy statements:
11/09/2018 8-K Other Events
10/17/2018 10-K/A Annual Report for the period ended July 31, 2018 [amend]
10/15/2018 10-K Annual Report for the period ended July 31, 2018
10/15/2018 8-K Quarterly results
10/15/2018 GN Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
09/27/2018 8-K Quarterly results
09/14/2018 4 JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Disposed of 787,163 shares @ $0
Acquired 787,163 shares @ $0
Disposed of 97,491 shares @ $0
Acquired 97,491 shares @ $0
Disposed of 32,711 shares @ $0
Acquired 32,711 shares @ $0
Disposed of 225,556 shares @ $0
Acquired 225,556 shares @ $0
09/07/2018 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Release"
  Next >>

Rocket Data Systems, Inc. © 2018 | Contact Us | Data Disclaimer | Terms of Use | Privacy